Department of Respiratory and Critical Care Medicine, The Fourth Affiliated Hospital, Zhejiang University School of Medicine, Yiwu, China.
School of Medicine, Zhejiang University, Hangzhou, China.
Front Immunol. 2023 May 29;14:1199631. doi: 10.3389/fimmu.2023.1199631. eCollection 2023.
Unprecedented breakthroughs have been made in cancer immunotherapy in recent years. Particularly immune checkpoint inhibitors have fostered hope for patients with cancer. However, immunotherapy still exhibits certain limitations, such as a low response rate, limited efficacy in certain populations, and adverse events in certain tumors. Therefore, exploring strategies that can improve clinical response rates in patients is crucial. Tumor-associated macrophages (TAMs) are the predominant immune cells that infiltrate the tumor microenvironment and express a variety of immune checkpoints that impact immune functions. Mounting evidence indicates that immune checkpoints in TAMs are closely associated with the prognosis of patients with tumors receiving immunotherapy. This review centers on the regulatory mechanisms governing immune checkpoint expression in macrophages and strategies aimed at improving immune checkpoint therapies. Our review provides insights into potential therapeutic targets to improve the efficacy of immune checkpoint blockade and key clues to developing novel tumor immunotherapies.
近年来，癌症免疫疗法取得了前所未有的突破。特别是免疫检查点抑制剂为癌症患者带来了希望。然而，免疫疗法仍存在一定的局限性，如反应率低、在某些人群中的疗效有限以及某些肿瘤中的不良反应。因此，探索可以提高患者临床反应率的策略至关重要。肿瘤相关巨噬细胞（TAMs）是浸润肿瘤微环境的主要免疫细胞，表达多种影响免疫功能的免疫检查点。越来越多的证据表明，TAMs 中的免疫检查点与接受免疫治疗的肿瘤患者的预后密切相关。本综述重点介绍了调节巨噬细胞中免疫检查点表达的调控机制以及旨在改善免疫检查点治疗的策略。我们的综述为提高免疫检查点阻断疗效的潜在治疗靶点提供了深入了解，并为开发新的肿瘤免疫疗法提供了关键线索。
